Pattern Bioscience

Pattern Bioscience, formerly known as Klaris Diagnostics, is an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections.

Pattern Bioscience aims to save lives by transforming how bacterial infections are diagnosed and to improve global health by reducing the burden of antibiotic resistance.

Pattern Bioscience was founded in 2016 by Nick Arab. The company is headquartered in Austin, Texas.

 

Pattern has developed Digital CultureTM, a single cell analysis platform that uses digital cell reactors combined with machine learning to rapidly diagnose complex bacterial infections. The platform, which produces millions of measurements per run, will zoom into the real-time antibiotic response of individual bacterial cells within the first critical hours of illness.

 

Pattern single-cell microbiology technology is the first and only culture-free, rapid phenotypic testing platform to deliver clinically actionable results in a timeframe that will enable healthcare teams to get appropriate, life-saving treatments to patients fast enough to make a real difference in outcomes.

 

Pattern’s first test, which was granted Breakthrough Device Designation from the FDA in December 2021, will be for hospitalized patients with pneumonia. In the future, Pattern’s technology will support a full menu of other tests.

 

Pattern Bioscience is backed by Illumina Ventures, Omnimed Capital, Antimicrobial Resistance Action Fund, Daleshaw Ltd., and others. The company raised $28.7M in a Series C round on Apr 27, 2023. This brings Pattern's total funding to $67.2M to date.

 

 

  • Year founded: 2016
  • Funding Info: $67.2M over 5 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Austin
  • State: Texas
  • Country: United States
Related businesses